Diffuse malignant peritoneal mesothelioma (DMPM) a rare diagnosis

被引：3

作者：

Habbel, Victoria Susanne Antonia ^{[1
]}

Mahler, Elisa Annabelle ^{[2
]}

Feyerabend, Bernd ^{[3
]}

Oldhafer, Karl-Jurgen ^{[1
]}

Lipp, Michael Josef ^{[1
]}

机构：

[1] Semmelweis Univ, Med Fak, Asklepios Campus Hamburg, Hamburg, Germany

[2] Asklepios Klin Barmbek, Klin Allgemein & Viszeralchirurg, Chirurg Onkol, Hamburg, Germany

[3] MVZ Hanse Histologikum GmbH, Hamburg, Germany

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2020年 / 58卷 / 02期

关键词：

malignant peritoneal mesothelioma; cytoreductive surgery; CRS; hyperthermic intraperitoneal chemotherapy; HIPEC; CYTOREDUCTIVE SURGERY; INTRAPERITONEAL CHEMOTHERAPY; COMPUTED-TOMOGRAPHY; CANCER; EPIDEMIOLOGY; MANAGEMENT; RADIATION; SURVIVAL;

D O I：

10.1055/a-1083-6962

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare diagnosis, found more frequently in men than in women. Symptoms are unspecific abdominal disorders making that diagnosis difficult to set. Causes of DMPM are yet to be discovered in entirety. Asbestos exposure is the reason for approximately 7 % of all peritoneal mesotheliomas. Until the evaluation of systematic cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) DMPM was a fatal diagnosis with a median overall survival (OS) of 4-13 months. The prognosis of DMPM dramatically improved with implementation of CRS and HIPEC to an OS of 30-92 month nowadys. CRS and HIPEC were performed in this case.

引用

页码：146 / 151

页数：6

共 40 条

[1] Clinical presentation of peritoneal mesothelioma [J].

Acherman, YI ;

Welch, LS ;

Bromley, CM ;

Sugarbaker, PH .

TUMORI, 2003, 89 (03) :269-273

[2] Diagnosis and management of patients with malignant peritoneal mesothelioma [J].

Alexander, H. Richard, Jr. ;

Burk, Allen P. .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (01) :79-86

[3] Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma [J].

Alexander, H. Richard, Jr. ;

Bartlett, David L. ;

Pingpank, James F. ;

Libutti, Steven K. ;

Royal, Richard ;

Hughes, Marybeth S. ;

Holtzman, Matthew ;

Hanna, Nader ;

Turner, Keli ;

Beresneva, Tatiana ;

Zhu, Yue .

SURGERY, 2013, 153 (06) :779-786

[4]

[Anonymous], ONCOLOGY WILLISTON P

[5]

[Anonymous], ONCOLOGY WILLISTON P

[6]

[Anonymous], ONCOLOGY WILLISTON P

[7] Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion [J].

Baratti, Dario ;

Kusamura, Shigeki ;

Martinetti, Antonia ;

Seregni, Ettore ;

Oliva, Daniela G. ;

Laterza, Barbara ;

Deraco, Marcello .

ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) :500-508

[8] Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma [J].

Chang, Ellen T. ;

Lau, Edmund C. ;

Mowat, Fionna S. ;

Teta, M. Jane .

CANCER CAUSES & CONTROL, 2017, 28 (09) :971-979

[9] Malignant mesothelioma after radiation treatment for Hodgkin lymphoma [J].

De Bruin, Marie L. ;

Burgers, Jacobus A. ;

Baas, Paul ;

van't Veer, Mars B. ;

Noordijk, Evert M. ;

Louwman, Marieke W. J. ;

Zijlstra, Josee M. ;

van den Berg, Hendrik ;

Aleman, Berthe M. P. ;

van Leeuwen, Flora E. .

BLOOD, 2009, 113 (16) :3679-3681

[10]

Eltabbakh GH, 1999, J SURG ONCOL, V70, P6, DOI 10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.3.CO

← 1 2 3 4 →